Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 3/2015

01.03.2015 | Review Article

Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer

verfasst von: Ali Akbar Samadani, Haleh Akhavan-Niaki

Erschienen in: Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer may appear by frequent genetic or epigenetic changes in oncogenes, tumor suppressor or DNA mismatch repair genes. Molecular studies show the possibility of involvement of certain cancer pathways in gastric cancer. In this respect, DNA methylation is one of the most important epigenetic alterations in gastric cancer and identifying the signaling mechanism and also methylation of some genes that are involved in gastric cancer can help to improve treatment strategies. Relatively, there are many reported methylation alteration of genes in stem cells in all kinds of tumors with some of these genes having a key role in tumor development. Correspondingly, KLF5, CDX1/2, WNT1 and FEM1A are considerable genes in gastric cancer, although many researches and studies have illustrated that sonic hedgehog and expression of its signaling cascade proteins are related in gastric cancer. Relatively, modification in these genes causes many eclectic cancers such as rhabdomyosarcoma and diverse kinds of digestive system tumor development. Conspicuously, these master genes have a noticeable role in stem cell’s growth regulation as well as other kinds of cancer such as breast cancer and leukemia. Hence, we concluded that research and studies on methylation and expression of these genes and also the investigation of molecular signaling in gastric cancer can acquire impressive conclusions in order to control and treat this common place and serious problem.
Literatur
1.
2.
Akhavan-Niaki H, Samadani AA. Molecular insight in gastric cancer induction: an overview of cancer stemness genes. Cell Biochem Biophys. 2014;68(3):463–73.CrossRefPubMed
3.
Garcia-Gonzalez MA, et al. Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol. 2007;102(9):1878–92.CrossRefPubMed
4.
Forbes SA, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10: p. Unit 10 11.
5.
Yoshikawa A, et al. Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression. Gastric Cancer. 1998;1(2):134–41.CrossRefPubMed
6.
7.
Chen SY, et al. An overview of concepts for cancer stem cells. Cell Transplant. 2011;20(1):113–20.CrossRefPubMed
8.
Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys. 2013;67(2):501–13.CrossRefPubMed
9.
Zhang YJ, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13(8):2378–84.CrossRefPubMed
10.
11.
Ramirez JL, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group. J Clin Oncol. 2005;23(36):9105–12.CrossRefPubMed
12.
Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14(3):204–20.CrossRefPubMed
13.
Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253–66.CrossRefPubMed
14.
Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 2001;414(6861):277–83.CrossRefPubMed
15.
Jackson JP, et al. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature. 2002;416(6880):556–60.CrossRefPubMed
16.
17.
Wong TS, et al. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer. 2003;39(13):1881–7.CrossRefPubMed
18.
Soon MS, et al. Expression of Kruppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan. Virchows Arch. 2011;459(2):161–6.CrossRefPubMed
19.
Tsukamoto T, et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2004;130(3):135–45.CrossRefPubMed
20.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54.CrossRefPubMed
21.
Noto JM, et al. Helicobacter pylori promotes the expression of Kruppel-like factor 5, a mediator of carcinogenesis, in vitro and in vivo. PLoS ONE. 2013;8(1):e54344.PubMedCentralCrossRefPubMed
22.
Ogino S, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–6.PubMedCentralCrossRefPubMed
23.
Wang C, et al. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology. 2003;64(3):259–65.CrossRefPubMed
24.
25.
26.
Fujii Y, et al. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness-associated reprogramming factors SALL4 and KLF5. Proc Natl Acad Sci USA. 2012;109(50):20584–9.PubMedCentralCrossRefPubMed
27.
Almeida R, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199(1):36–40.CrossRefPubMed
28.
Eda A, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol. 2002;37(2):94–100.CrossRefPubMed
29.
Bonner CA, Loftus SK, Wasmuth JJ. Isolation, characterization, and precise physical localization of human CDX1, a caudal-type homeobox gene. Genomics. 1995;28(2):206–11.CrossRefPubMed
30.
Mizoshita T, et al. Expression of the intestine-specific transcription factors, Cdx1 and Cdx2, correlates shift to an intestinal phenotype in gastric cancer cells. J Cancer Res Clin Oncol. 2004;130:29–36.CrossRefPubMed
31.
Bai Y, et al. Distinct expression of CDX2 and GATA4/5, development-related genes, in human gastric cancer cell lines. Mol Carcinog. 2000;28(3):184–8.CrossRefPubMed
32.
Lee CS, et al. SHH-N upregulates Sfrp2 to mediate its competitive interaction with WNT1 and WNT4 in the somitic mesoderm. Development. 2000;127(1):109–18.PubMed
33.
Tanaka K, et al. The evolutionarily conserved porcupine gene family is involved in the processing of the Wnt family. Eur J Biochem. 2000;267(13):4300–11.CrossRefPubMed
34.
Tice DA, et al. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem. 2002;277(16):14329–35.CrossRefPubMed
35.
Griffiths EA, et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer. 2007;96(1):95–103.PubMedCentralCrossRefPubMed
36.
Ventura-Holman T, et al. The Fem1a gene is downregulated in Rhabdomyosarcoma. Tumour Biol. 2005;26(6):294–9.CrossRefPubMed
37.
38.
Maher JF, et al. FEM1A is a candidate gene for polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(6):330–5.CrossRefPubMed
39.
Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12(2):192–8.PubMedCentralPubMed
40.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99.CrossRefPubMed
41.
Ruiz i Altaba A. Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development. 1999;126(14):3205–16.PubMed
42.
Schetter AJ, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res. 2009;15(18):5878–87.PubMedCentralCrossRefPubMed
43.
44.
Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol. 2011;26(1):19–27.CrossRefPubMed
45.
Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168–74.CrossRefPubMed
46.
Lu X, et al. Differential regulation of CDX1 and CDX2 gene expression by deficiency in methyl group donors. Biochimie. 2008;90(5):697–704.CrossRefPubMed
47.
Gendron FP, et al. The CDX2 transcription factor regulates furin expression during intestinal epithelial cell differentiation. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G310–8.CrossRefPubMed
48.
Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004;3(7):593–601.CrossRefPubMed
49.
Silberg DG, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology. 2002;122(3):689–96.CrossRefPubMed
50.
Almeida R, et al. OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol. 2005;207(4):396–401.CrossRefPubMed
51.
Zhang H, Xue Y. Wnt pathway is involved in advanced gastric carcinoma. Hepatogastroenterology. 2008;55(84):1126–30.PubMed
52.
Meireles SI, et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa. Cancer Res. 2004;64(4):1255–65.CrossRefPubMed
53.
Fujiwara K, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005;11(3):1219–25.PubMed
54.
Samadani AA, Nikbakhsh N, Fattahi S, Pourbagher R, Aghajanpour Mir SM, Mousavi Kani N, Abedian Z, Akhavan-Niaki, H. RNA extraction from animal and human’s cancerous tissues: does tissue matter? Int J Mol Cell Med. 2015;4(1):54–9.
Metadaten
Titel
Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer
verfasst von
Ali Akbar Samadani
Haleh Akhavan-Niaki
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0492-3

Weitere Artikel der Ausgabe 3/2015

Medical Oncology 3/2015 Zur Ausgabe

Original Paper

Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2

Original Paper

OCH-mediated shift of Th1 and Th2 cytokines by NKT cells in mice with aplastic anemia

Original Paper

Radiation sensitization with sodium nitrite in patients with brain metastases: a pilot randomized controlled trial

Erratum

Erratum to: The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy

Original Paper

Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib

Original Paper

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise